Genaera Discontinues Phase II Studies Of Lomucin And Squalamine
This article was originally published in The Pink Sheet Daily
Executive Summary
Termination of the studies reflects Genaera’s decision to focus on core assets trodusquemine for obesity and anti-IL-9 program for asthma.
You may also be interested in...
Genaera Shifts Focus From AMD To Obesity
Company switches gears in the wake of Genentech’s Lucentis launch.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.